What is claimed is,

1. A pharmaceutical dosage form comprising an undissolved form of (2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methylbutanoyl]-amino-1,6-diphenylhexane (ABT-378; lopinavir) in a therapeutically effective amount.

2. The dosage form according to claim 1 further comprising (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-amino-1,6-diphenyl-3hydroxyhexane (ritonavir).

3. The dosage form according to claim 2 wherein the lopinavir and ritonavir are present in the dosage form in a ratio of 4:1.

4. The dosage form according to claim 1 wherein the lopinavir is in an amorphous form.

5. The dosage form according to claim 4 wherein the lopinavir is in a solid dispersion or solid solution.

6. A pharmaceutical dosage form comprising at an undissolved HIV protease inhibitor in a therapeutically effective amount wherein upon administration of a single dose of the protease inhibitor to each member of a study population, the mean of a AUC∞ (fed) over AUC∞ (fasted) ratio for the members of the study population is in the range of about 0.7 to about 1.43.

7. A pharmaceutical dosage formulation comprising an undissolved HIV protease inhibitor in a therapeutically effective amount wherein upon administration of a single dose of the protease inhibitor to each member of a study population, the mean of a Cmax (fed) over Cmax (fasted) ratio for the members of the study population is in the range of about 0.7 to about 1.43.

8. A pharmaceutical dosage form comprising an undissolved HIV protease inhibitor in a therapeutically effective amount wherein upon administration of a single dose of the protease

inhibitor to each member of a study population, the difference in AUC∞ between a 95th percentile of the study population the and a 5th percentile of the study population is less than about 180.

9. A pharmaceutical dosage form comprising an undissolved HIV protease inhibitor in a therapeutically effective amount wherein upon administration of a single dose of the protease inhibitor to each member of a study population under fasting conditions, the difference in Cmax between the 95th percentile of the study population and the 5th percentile of the study population is less than about 15.

10. The dosage form of any one of claims 6-9 wherein the HIV protease inhibitor is **(2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methylbutanoyl]-amino-1,6-diphenylhexane (ABT-378; lopinavir);**

11. The dosage form of any one of claims 6-9 wherein the HIV protease inhibitor is **(2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methylbutanoyl]-amino-1,6-diphenylhexane** (ABT-378; lopinavir) and said dosage form further comprises **(2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-amino-1,6-diphenyl-3hydroxyhexane (ritonavir).**

12. A pharmaceutical dosage form comprising lopinavir in a therapeutically effective amount, said dosage form providing an in vitro dissolution profile using a USP apparatus 2 (paddle) at 75 rpm with a 0.06M POE10LE (Polyoxyethylene 10 Lauryl Ether) medium at 37°C wherein:
about 20 % to about 30 % of lopinavir is released from about 0 to about 15 minutes;
about 43 % to about 63 % of lopinavir is released from about 15 to about 30 minutes;
about 61.3 % to about 81.7 % of lopinavir is released from about 30 to about 45 minutes; and
about 75.4 % to about 93.2 % of lopinavir is released from about 45 to about 60 minutes.

13. A pharmaceutical dosage form comprising ritonavir in a therapeutically effective amount, said dosage form providing an in vitro dissolution profile using a USP apparatus 2 (paddle) at 75 rpm with a 0.06M POE10LE (Polyoxyethylene 10 Lauryl Ether) medium at 37°C wherein:

about 19.8 % to about 34.4 % of ritonavir is released from about 0 to about 15 minutes;
about 41.6 % to about 76.5 % of ritonavir is released from about 15 to about 30 minutes;
about 59.4 % to about 91.1 % of ritonavir is released from about 30 to about 45 minutes; and
about 73.4 % to about 95 % of ritonavir is released from about 45 to about 60 minutes.

14. A method of treating HIV/AIDS by administering to a subject in need thereof the pharmaceutical dosage form of any one of claim 1.

Dated this 30th day of August 2007

Of AnandAnd Anand Advocates
Attorney for the Applicant